Insilico Medicine Initiates First-in-Human Study of ISM001-055, a Novel Drug Discovered Using Insilico's Proprietary End-to-end Artificial Intelligence Platform

NEW YORK and HONG KONG, Nov. 30, 2021 /PRNewswire/ -- Insilico Medicine, an end-to-end artificial intelligence (AI)-driven drug discovery company, today announced that the first healthy volunteer has been dosed in a first-in-human microdose trial of ISM001-055.

ISM001-055 is a potentially first-in-class small molecule inhibitor of a novel biological target discovered by Pharma.AI, Insilico Medicine's end-to-end AI-powered drug discovery platform. It is being developed for the treatment of idiopathic pulmonary fibrosis (IPF), a chronic lung disease which results in progressive and irreversible decline in lung function. After completing IND-enabling studies, Insilico Medicine has initiated the microdose trial to begin characterizing the pharmacokinetic profile in humans. The trial, administering ISM001-055 intravenously in healthy volunteers, is being conducted in Australia.

ISM001-055 demonstrated highly promising results in multiple preclinical studies including in vitro biological studies, pharmacokinetic and safety studies. The compound significantly improved myofibroblast activation which contributes to the development of fibrosis. ISM001-055's novel target is potentially relevant to a broad range of fibrotic indications.

"We are very pleased to see Insilico Medicine's first antifibrotic drug candidate entering into the clinic. We believe this is a significant milestone in the history of AI-powered drug discovery because to our knowledge the drug candidate is the first ever AI-discovered novel molecule based on an AI-discovered novel target. We have leveraged our end-to-end AI-powered drug discovery platform, including the usage of generative biology and generative chemistry, to discover novel biological targets and generate novel molecules with drug-like properties. ISM001-055 is the first such compound to enter the clinic, and we expect more to come in the near future," said Feng Ren, Ph.D., CSO of Insilico Medicine.

Previously, Insilico Medicine demonstrated its ability to generate drug-like hit molecules using AI with the publication of the Generative Tensorial Reinforcement Learning (GENTRL) system for a well-known target in record time. It also demonstrated the target's proof of concept by applying deep learning techniques for the identification of novel biological targets. This novel antifibrotic program combined these target discovery and generative chemistry capabilities. Notably, Insilico Medicine completed the entire discovery process from target discovery to preclinical candidate nomination within 18 months on a budget of $2.6 million.

"Insilico Medicine has achieved this breakthrough milestone which is extremely impressive. Many drugs were discovered accidentally when scientists designed a drug for disease A and then they found out that it actually works for some different disease B. AI is a way to search for information and look for signals for drug discovery. This achievement didn't happen by chance and is a reproducible method and procedure which is revolutionary," said Michael Levitt, 2013 Nobel Laureate in Chemistry and member of Insilico Medicine's Scientific Advisory Board.

"What impresses me the most about this achievement is not only the lower cost or faster speed of development but, also it demonstrated the Pharma AI platform can overcome the low probability of getting to this stage," said Alex Zhavoronkov, Ph.D., Founder and CEO of Insilico Medicine. "There are very few examples of a pharmaceutical company discovering a new target for a broad range of diseases, designing a novel molecule, and initiating human clinical trials. To my knowledge, nobody has achieved this with AI to-date. The failure rates in preclinical target discovery are very high and even after the targets are validated in animal models, over half of Phase 2 clinical trials fail primarily due to the choice of target. Target discovery is the fundamental grand challenge of the pharmaceutical industry. With ISM001-055 we used end-to-end AI connecting biology, chemistry in order to assess activity and safety in multiple preclinical models."

About Insilico Medicine

Insilico Medicine, an end-to-end artificial intelligence (AI)-driven drug discovery company, is connecting biology, chemistry, and clinical trials analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques to discover novel targets and to design novel molecular structures with desired properties. Insilico Medicine is delivering breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system (CNS) diseases and aging-related diseases. For more information, visit www.insilico.com.

Media Contact
For further information, images, or interviews, please contact pr@insilico.com  

Photo - https://mma.prnewswire.com/media/1698965/FIH_Announce_FB.jpg